Bladder Cancer Journal Vol. 11, Issue 2 – April – June 2025
Higher resilience in radical cystectomy patients is associated with improved health related...
Read More
Topic: Bladder Cancer
Role of DNA Repair Mutations in Sensitivity to Cisplatin-based Chemotherapy
Gopalkumar Iyer, MD, explores the role of genomic alterations in predicting response to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Read More
Grade Group 1 at Biopsy – Do We Need to Know More?
John W. Davis, MD, FACS, explores prostate cancer diagnostics and management, focusing on grade group one disease.
Read More
Neoadjuvant Chemo vs. I/0 vs. ADCs
Daniel P. Petrylak, MD, explores neoadjuvant and adjuvant therapies in urothelial carcinoma in patients with muscle-invasive bladder cancer.
Read More
MRI-Assisted Radiosurgery (MARS) Management of High Risk and Recurrent Prostate Cancer
Steven J. Frank, MD, FACR, FABS, FASTRO, discusses advancements in MRI-assisted radiosurgery (MARS) for prostate cancer.
Read More
Intermediate-Risk NMIBC/BCG Naïve: Treatment of Choice
Leonard G. Gomella, MD, FACS, explores bladder cancer treatment, particularly in the context of intermediate-risk, BCG-naïve disease.
Read More
Bladder Cancer Journal Vol. 11, Issue 1 – January – March 2025
Clinical trials corner issue 11(1) Abstract: Dear Readers, In this issue, we highlight recently...
Read More
High-Risk/BCG Naïve: Treatment of Choice
Michael A. O’Donnell, MD, discusses BCG’s role as the standard treatment for non-muscle invasive bladder cancer (NMIBC).
Read More
Bladder Cancer Biomarkers: Surveillance
Yair Lotan, MD, discusses urinary biomarkers and highlights their evolving role in bladder cancer detection and surveillance.
Read More
Highlights of NCCN/AUA Guidelines 2024
Siamak Daneshmand, MD, covers recent updates in bladder cancer guidelines, focusing on the 2024 NCCN and AUA recommendations.
Read More
Role of Systemic Therapies in NMIBC
Amirali Salmasi, MD, MSCR, explores the rationale for systemic immunotherapy in non-muscle invasive bladder cancer.
Read More
Role of CtDNA in Bladder Cancer
Alexandra Drakaki, MD, PhD, explores circulating tumor DNA in bladder cancer, highlighting its potential as a biomarker.
Read More